Pancreatic cancer nursing: a complete reference for nursing students

Pancreatic cancer is among the most lethal malignancies in the United States, with a five-year overall survival rate of approximately 12%. The American Cancer Society estimates roughly 66,000 new diagnoses and 51,000 deaths annually — making pancreatic cancer the third leading cause of cancer death despite being only the twelfth most common cancer by incidence. The gap between incidence and mortality reflects a disease biology defined by late presentation, aggressive local invasion, and early systemic spread.

Nurses encounter pancreatic cancer patients across every setting: in the surgical ICU after a Whipple procedure, in infusion centers managing FOLFIRINOX toxicities, in endoscopy suites during biliary stenting procedures, and in palliative care supporting patients with advanced disease. NCLEX tests this topic reliably — Whipple post-op complications, CA 19-9 interpretation, and chemotherapy toxicity management all appear with regularity. This reference covers the clinical foundation needed to care confidently for these patients.

Quick reference

Pathophysiology and classification

Tumor types

The pancreas has two functionally distinct compartments — exocrine and endocrine — and tumors arising from each behave very differently.

Exocrine tumors arise from the ductal or acinar cells that produce and transport digestive enzymes. Pancreatic ductal adenocarcinoma (PDAC) is overwhelmingly the most important: it accounts for approximately 90% of all pancreatic malignancies, originates from ductal epithelial cells, and carries the dismal prognosis most people associate with “pancreatic cancer.” Other exocrine tumors include:

• Intraductal papillary mucinous neoplasms (IPMN): Mucin-producing tumors arising in the main pancreatic duct or branch ducts. IPMNs exist on a spectrum from benign to invasive carcinoma and are often discovered incidentally on imaging. Main-duct IPMNs carry a much higher malignant potential than branch-duct IPMNs.
• Acinar cell carcinoma: Rare; arises from enzyme-secreting acinar cells. May secrete lipase, causing a paraneoplastic syndrome of subcutaneous fat necrosis and polyarthralgia.
• Pancreatoblastoma: Rare pediatric tumor.

Endocrine tumors arise from the islet cells of Langerhans and are collectively called pancreatic neuroendocrine tumors (PNETs or pNETs). These include insulinomas (most common, hypoglycemia), glucagonomas (necrolytic migratory erythema, diabetes), gastrinomas (Zollinger-Ellison syndrome, peptic ulcer disease), and VIPomas (watery diarrhea, hypokalemia, achlorhydria). PNETs generally behave more indolently than PDAC, though high-grade neuroendocrine carcinomas are aggressive. PNETs are distinct enough in their presentation, treatment, and prognosis that NCLEX typically tests them separately.

Anatomy and why location determines prognosis

The pancreas lies in the retroperitoneum, posterior to the stomach. It is anatomically divided into head, uncinate process, neck, body, and tail.

Head tumors (70–80% of PDAC): Because the head of the pancreas wraps around the common bile duct (CBD) as it traverses toward the ampulla of Vater, even small head tumors compress the CBD early. This produces obstructive jaundice — a visible, symptomatic sign that brings patients to medical attention while the tumor is still potentially resectable. This is the paradox of pancreatic cancer: the location that seems most dangerous (proximity to critical ductal structures) is actually the location associated with earlier detection and higher resectability rates.

Body and tail tumors: No biliary structures are compressed. Tumors grow silently until they invade the splenic vessels, celiac axis, or superior mesenteric artery — or until peritoneal spread causes ascites. By the time body and tail tumors are symptomatic, they are almost always locally advanced or metastatic. This is why body/tail PDAC carries a worse prognosis than head PDAC: not because the biology differs greatly, but because the anatomic silence of that location allows progression before detection.

Why prognosis is so poor

Several features compound to make PDAC uniquely lethal:

• Retroperitoneal location: No capsule, no barriers. The tumor grows directly into the superior mesenteric artery, celiac axis, portal vein, and adjacent viscera. The absence of anatomical containment allows invasion without resistance.
• Desmoplastic stroma: PDAC generates a dense fibrous stroma around the tumor — the desmoplastic reaction. This stroma compresses blood vessels, creating a hypoxic, hypoperfused microenvironment that shields tumor cells from chemotherapy and immune surveillance.
• Late presentation: Approximately 80–85% of PDAC is diagnosed at locally advanced or metastatic stage, when surgical cure is not possible.
• Early hematogenous spread: PDAC metastasizes early to the liver (most common), lungs, and peritoneum — often before the primary tumor is detected.
• Limited chemotherapy sensitivity: Even in metastatic disease, the most active regimens (FOLFIRINOX, gemcitabine + nab-paclitaxel) extend median survival from ~6 months to ~11–12 months — a meaningful improvement, but still far from curative.

Patients with chronic pancreatitis develop cellular changes over time that elevate cancer risk, making monitoring and early symptom recognition a nursing priority for this population.

Risk factors

Modifiable risk factors

• Tobacco smoking: The strongest modifiable risk factor. Smokers have approximately twice the risk of PDAC compared with never-smokers. Risk is dose-dependent and begins to decline approximately 10 years after cessation.
• Chronic pancreatitis: Chronic inflammation drives ductal cell turnover and accumulation of mutations. The risk is highest in patients with hereditary pancreatitis (PRSS1 mutations), who may have a lifetime PDAC risk exceeding 40%.
• Type 2 diabetes mellitus (T2DM): Long-standing T2DM is associated with a 1.5- to 2-fold increased risk. The relationship is bidirectional — new-onset diabetes in an older adult without a clear precipitant can be an early paraneoplastic manifestation of pancreatic cancer, not merely a risk factor.
• Obesity: Adiposity, particularly central adiposity, increases PDAC risk independently of diabetes. The mechanism likely involves insulin resistance, adipokine dysregulation, and chronic low-grade inflammation.
• Heavy alcohol use: A risk factor primarily through its role in causing chronic pancreatitis rather than a direct carcinogen.
• Diet: High intake of red and processed meat, low fruit and vegetable consumption — associations are modest compared with tobacco and pancreatitis.

Non-modifiable and genetic risk factors

• Age: Median age at diagnosis is 71. PDAC is rare before age 45.
• Sex: Slightly higher incidence in males, though the gap is narrowing.
• Race: Black Americans have higher incidence and mortality rates than white Americans, likely reflecting a combination of social determinants, access to care, and genetic factors.
• Family history: Approximately 10% of PDAC is familial. Having a first-degree relative with PDAC increases risk 2-fold; two or more affected first-degree relatives raise the risk substantially higher.
• Hereditary cancer syndromes:
  • BRCA2 mutations: Highest attributable hereditary risk for PDAC (~5–7% of familial cases). BRCA1 mutations also increase risk but less strongly.
  • PALB2 mutations: Increasingly recognized as a significant PDAC risk gene; also confers high breast cancer risk.
  • Lynch syndrome (MMR gene mutations): Modest elevation in PDAC risk; primarily important for other cancers.
  • CDKN2A mutations: Associated with familial atypical multiple mole melanoma (FAMMM) syndrome; 17-fold increased PDAC risk.
  • STK11/LKB1 (Peutz-Jeghers syndrome): Highest relative risk of any hereditary syndrome for PDAC (~130-fold).
  • Hereditary pancreatitis (PRSS1): Lifetime PDAC risk up to 40%.

Clinical presentation

The classic triad: head of pancreas tumor

The textbook presentation of pancreatic head cancer combines three findings:

1. Painless obstructive jaundice: The tumor compresses the CBD as it runs through the head of the pancreas. Bile backs up into the bloodstream — bilirubin rises, skin and sclera yellow, urine becomes tea-colored (conjugated hyperbilirubinemia), and stools become pale/acholic (clay-colored) as bile pigment is diverted away from the intestinal tract. The jaundice is typically painless, which distinguishes it from the painful jaundice of gallstone obstruction.
2. Weight loss: Profound and unintentional — driven by exocrine insufficiency (malabsorption), anorexia, early satiety, and cancer cachexia. Weight loss preceding diagnosis by months is common.
3. Epigastric pain radiating to the back: Reflects perineural invasion or direct invasion of the celiac plexus. The pain is typically dull, persistent, and worsens in the supine position; patients often lean forward for relief — a characteristic posture that nursing assessments should recognize.

Courvoisier’s sign

A palpable, nontender gallbladder in a jaundiced patient is Courvoisier’s sign. The clinical reasoning: in gallstone disease, the gallbladder becomes fibrotic and contracted from chronic inflammation and cannot distend. In malignant biliary obstruction — pancreatic head cancer, cholangiocarcinoma, ampullary cancer — the gallbladder is normal and distends as bile backs up behind the obstruction, producing a palpable mass in the right upper quadrant. Courvoisier’s sign therefore suggests malignant obstruction rather than gallstones, and warrants urgent oncologic workup.

Additional signs and symptoms

• Steatorrhea: Foul-smelling, oily, floating stools from fat malabsorption — a sign of exocrine pancreatic insufficiency. The tumor obstructs the pancreatic duct, preventing digestive enzymes from reaching the small intestine. Patients describe stools that are difficult to flush.
• New-onset diabetes: As mentioned above, new-onset T2DM in an older adult — particularly without obesity or family history — can be a paraneoplastic sign of occult PDAC. The mechanism involves destruction of islet tissue and tumor-secreted factors that induce insulin resistance.
• Trousseau’s sign (migratory thrombophlebitis): Spontaneous, recurrent thrombophlebitis migrating from vein to vein. First described by Armand Trousseau (who reportedly diagnosed his own gastric cancer based on this finding). This is distinct from Trousseau’s sign of hypocalcemia (carpal spasm with blood pressure cuff inflation). Migratory thrombophlebitis in the absence of clear precipitants is a paraneoplastic phenomenon associated with visceral malignancies, particularly pancreatic, gastric, and lung cancers. Venous thromboembolism risk in PDAC is among the highest of any solid tumor — see DVT nursing for VTE assessment and management principles.
• Pruritus: Intense generalized itching from bile salt deposition in the skin — a consequence of obstructive jaundice. It is often one of the most distressing symptoms patients report.
• Ascites: Usually indicates peritoneal spread or portal hypertension from hepatic metastases. The presence of ascites generally indicates unresectable disease.

Why body and tail tumors present differently

Body and tail tumors do not compress the CBD, so jaundice does not occur early. Presentation is dominated by pain (back and epigastric), weight loss, and new-onset diabetes — nonspecific findings that delay diagnosis. Splenic vein thrombosis from body/tail tumors can cause isolated gastric varices and upper GI bleeding. Nurses caring for patients presenting with unexplained left-sided portal hypertension findings should consider pancreatic body/tail pathology.

Diagnosis and staging

Imaging

CT abdomen/pelvis with contrast (multiphase “pancreatic protocol” CT) is the primary staging tool. The pancreatic protocol uses arterial and venous phase imaging to optimize visualization of the pancreatic parenchyma, vascular involvement, and liver metastases. The “double-duct sign” — simultaneous dilation of both the common bile duct and the pancreatic duct — is a classic CT finding in pancreatic head tumors and is highly suspicious for malignancy.

CT determines vascular involvement (superior mesenteric artery, celiac axis, portal vein, superior mesenteric vein) — the critical factor in assessing resectability.

MRI/MRCP (magnetic resonance cholangiopancreatography): Superior to CT for characterizing ductal anatomy and cystic lesions (particularly IPMNs). MRCP provides detailed mapping of the biliary and pancreatic duct systems without contrast or radiation.

Endoscopic ultrasound (EUS): A highly sensitive modality for detecting small tumors not visible on CT and for tissue acquisition via fine-needle aspiration or biopsy (EUS-FNA/FNB). EUS is also used for detailed local staging — assessing vascular involvement and lymph node status in ways CT cannot resolve. Nursing preparation for EUS is similar to upper endoscopy: NPO status, IV access, moderate sedation monitoring, throat numbness education, and post-procedure airway and vital sign monitoring.

PET/CT: Used selectively for detecting occult distant metastases, particularly before planned surgical resection. Not part of routine staging.

Tumor marker: CA 19-9

CA 19-9 (carbohydrate antigen 19-9) is a sialylated Lewis blood group antigen shed by PDAC cells. It is elevated in approximately 70–80% of patients with PDAC, and extremely high levels (>1,000 U/mL) are strongly associated with unresectable or metastatic disease.

Critical caveats for NCLEX and clinical practice:

• CA 19-9 is a monitoring and prognostic tool, not a screening or diagnostic test. A normal CA 19-9 does not rule out PDAC (sensitivity is only ~79%).
• Approximately 5–10% of the population is Lewis antigen-negative and will have an undetectable CA 19-9 regardless of tumor burden. Relying on CA 19-9 to exclude cancer in this population is a clinical error.
• CA 19-9 is elevated in benign conditions including cholangitis, biliary obstruction (any cause), cirrhosis, and IBD. An elevated CA 19-9 in an icteric patient does not confirm malignancy — biliary decompression must precede interpretation.
• Post-resection CA 19-9 trends are useful: a falling level suggests response; a rising level during surveillance suggests recurrence.

Biopsy

Tissue confirmation is required before initiating chemotherapy. For resectable disease, biopsy may be deferred until surgical pathology (to avoid seeding). For borderline resectable, locally advanced, or metastatic disease, EUS-FNA or CT-guided biopsy provides tissue. Molecular profiling (BRCA1/2, PALB2, KRAS, mismatch repair status) is increasingly standard on all biopsies to identify actionable alterations.

AJCC staging and resectability categories

AJCC TNM staging is used for prognostic classification. In pancreatic cancer, however, the clinical determination that matters most for treatment decisions is the resectability category, which is based primarily on vascular involvement:

Whipple procedure: post-op nursing care

The pancreaticoduodenectomy — universally called the Whipple procedure after Allen Oldfather Whipple, who popularized it in 1935 — is the only potentially curative surgery for pancreatic head cancer. It is one of the most complex abdominal operations performed, with a postoperative complication rate exceeding 50% even at high-volume centers. Understanding the procedure, its reconstructions, and its complications is a NCLEX priority.

What is removed

In a standard (non–pylorus-preserving) Whipple:

• Head of the pancreas and uncinate process
• Duodenum (entire first and second portions)
• Distal common bile duct
• Gallbladder
• Distal stomach (antrum)
• Regional lymph nodes

In a pylorus-preserving pancreaticoduodenectomy (PPPD): The pylorus and proximal duodenum are retained, which may reduce delayed gastric emptying rates and preserve gastric function — though outcomes data comparing standard vs pylorus-preserving are mixed.

Reconstruction

After resection, three anastomoses reconnect the digestive tract:

1. Pancreaticojejunostomy (or pancreaticogastrostomy): Remnant pancreas sutured to the jejunum (or stomach). This is the most technically challenging and the anastomosis most prone to leakage.
2. Hepaticojejunostomy: Common hepatic duct sutured to the jejunum, restoring biliary drainage.
3. Gastrojejunostomy (or duodenojejunostomy if pylorus-preserving): Stomach (or duodenum) anastomosed to the jejunum, restoring gastrointestinal continuity.

Post-op nursing priorities

Glucose management: The head of the pancreas contains the majority of the islet cell mass. Resection — even partial — significantly disrupts both insulin and glucagon secretion. In the immediate post-operative period, blood glucose is highly labile: stress hormones and enteral/parenteral nutrition drive hyperglycemia, while the reduced islet reserve limits compensatory insulin response. Glucose monitoring every 1–2 hours is standard in the ICU, with insulin infusion protocols typically targeting 140–180 mg/dL. After hospital discharge, many patients require long-term insulin therapy. Total pancreatectomy produces brittle diabetes (see below).

Nasogastric tube management: An NGT is placed intraoperatively and maintained post-op. Nurses should monitor NGT output character and volume, keep the tube patent, and not remove or advance the tube without surgical team orders.

Drain management: Surgical drains are placed at the hepaticojejunostomy and pancreaticojejunostomy sites. Drain amylase is measured on postoperative days 1 and 3 to screen for pancreatic fistula. Normal drain amylase mirrors serum amylase (30–110 U/L); drain amylase greater than three times the upper limit of normal on day 3 defines a biochemical leak and triggers fistula management protocols.

Nutritional support: Patients are NPO post-operatively. Parenteral nutrition (TPN) or jejunal tube feeding may be initiated early. As DGE resolves, the diet advances from sips to clears to low-fat solids. Pancreatic enzyme replacement therapy (PERT) — oral pancreatic enzymes (pancrelipase) — must be resumed with all meals and snacks once oral feeding begins. Without PERT, patients will develop significant fat malabsorption, steatorrhea, and nutritional deficiency. Fat-soluble vitamins (A, D, E, K) require supplementation.

Positioning: Semi-Fowler’s position (30–45°) reduces tension on the anastomoses and limits aspiration risk.

VTE prophylaxis: Pancreatic cancer patients carry among the highest VTE risk of any surgical oncology population — malignancy, prolonged surgery, and immobility all compound. Sequential compression devices (SCDs) are applied preoperatively and maintained. Low-molecular-weight heparin (LMWH) prophylaxis is initiated when drain output allows (typically postoperative day 1–2 unless bleeding risk is elevated).

Pain management: Post-Whipple pain is managed with multimodal analgesia — epidural analgesia (when available), IV analgesics, and transition to oral agents. Celiac plexus block may be performed intraoperatively for long-term pain control.

Wound care: Standard surgical wound monitoring for dehiscence, infection, and seroma.

Whipple complications: nursing assessment and intervention

Chemotherapy nursing care

Only approximately 15–20% of PDAC is resectable at diagnosis. For the majority of patients — those with locally advanced or metastatic disease — systemic chemotherapy is the primary treatment. Even for resected patients, adjuvant chemotherapy reduces recurrence risk and is now standard of care.

The two main regimens are FOLFIRINOX and gemcitabine + nab-paclitaxel. Selection is based primarily on performance status (PS), organ function, and patient preference.

FOLFIRINOX: oxaliplatin cold sensitivity — a nursing priority

Oxaliplatin produces a distinctive acute cold-hypersensitivity syndrome: exposure to cold temperatures or cold objects triggers acute laryngopharyngeal dysesthesia (throat tightening, difficulty swallowing — not true laryngospasm), and peripheral dysesthesias (painful tingling, electric shock sensations in hands and feet). This occurs within hours of infusion and can last 3–5 days.

Nursing education before the first FOLFIRINOX cycle must include:

• Avoid drinking cold beverages during and for 5 days after infusion
• Do not eat cold foods (ice cream, cold salads, refrigerated items directly from the fridge)
• Do not touch cold objects without gloves — metal poles, refrigerator shelves, car door handles in cold weather
• Wear gloves and close-toed shoes in cold environments
• Report throat tightness or swallowing difficulty (reassure that it is nerve sensitivity, not an allergic reaction, but report it nonetheless)

The cumulative sensory neuropathy from oxaliplatin develops over multiple cycles and may be dose-limiting. Assess neuropathy at every visit using a graded scale (NCI CTCAE).

Palliative and supportive care

The majority of pancreatic cancer patients are not candidates for curative resection. Palliative care is not a last resort — it is a parallel track, and nursing plays a central role in its delivery from diagnosis onward.

Biliary decompression

Obstructive jaundice from pancreatic head compression causes pruritus, cholangitis risk, fat malabsorption, and coagulopathy (from vitamin K malabsorption). Biliary stenting via ERCP (endoscopic retrograde cholangiopancreatography) places a plastic or metal stent through the CBD obstruction, restoring bile flow into the duodenum.

• Metal stents (SEMS) remain patent longer (6–12 months) than plastic stents (3 months) and are preferred in patients with expected survival beyond 3 months.
• Percutaneous transhepatic biliary drainage (PTBD): Used when ERCP is technically impossible (post-Whipple anatomy, tumor involvement at the hilum). An external catheter drains bile percutaneously.

Nursing: post-ERCP biliary stenting:

• Monitor for cholangitis: fever + jaundice + RUQ pain = Charcot’s triad — escalate immediately. The addition of hypotension and altered mental status (Reynolds’ pentad) indicates septic cholangitis requiring urgent biliary drainage and IV antibiotics.
• Monitor serum bilirubin and LFTs — expect improvement within 1–2 weeks of successful stenting.
• Educate patient about stent occlusion symptoms (return of jaundice, itching, dark urine, pale stools) and to seek care promptly.
• For PTBD: drain site care, output measurement, signs of infection at insertion site.

Patients with biliary involvement and hepatic complications benefit from principles covered in liver failure nursing — coagulopathy management, hepatic encephalopathy awareness, and ascites care all intersect here.

Pain management: celiac plexus block

Pancreatic cancer pain is mediated largely through the celiac plexus — the neural network anterior to the aorta at the level of the celiac axis. Celiac plexus neurolysis (EUS-guided or CT-guided injection of alcohol or local anesthetic into the celiac plexus) can produce significant, durable pain relief and reduces opioid requirements. It is typically offered to patients with refractory pain despite opioid optimization.

Pancreatic enzyme replacement therapy (PERT)

PERT (pancrelipase — a mixture of lipase, protease, and amylase derived from porcine pancreas) is essential for any patient with exocrine pancreatic insufficiency — whether from tumor obstruction, pancreatectomy, or chronic pancreatitis.

Nursing education for PERT:

• Take with every meal and every snack — not before or after, but during eating (enzymes must be present in the duodenum simultaneously with food)
• Do not crush or chew enteric-coated capsules — they are designed to release enzymes in the duodenum, not the stomach
• Dose is adjusted based on symptom response (steatorrhea, bloating, weight)
• Report persistent steatorrhea — may indicate inadequate dosing or non-adherence

Post-pancreatectomy diabetes

Diabetes following partial pancreatectomy ranges from new insulin-dependence (common after Whipple) to brittle diabetes after total pancreatectomy. The critical distinction:

In typical type 1 or type 2 DM, the alpha cells remain intact and secrete glucagon in response to hypoglycemia — providing a hormonal counterregulatory defense. After total pancreatectomy, both insulin-secreting beta cells and glucagon-secreting alpha cells are destroyed. Without glucagon:

• Hypoglycemia is severe and difficult to recognize in time
• Counter-regulatory responses are blunted
• Hypoglycemia risk exceeds that of classic type 1 DM in many patients

Management requires conservative insulin dosing, frequent glucose monitoring, liberal hypoglycemia thresholds, and intensive patient/family education about hypoglycemia recognition and glucagon kit use (though glucagon kits are less effective without endogenous glucagon — glucose gel, IV dextrose, or glucagon infusion may be required in severe cases).

Nurses should connect post-pancreatectomy patients with endocrinology and diabetes education early. For foundational DM nursing principles, see the diabetes mellitus nursing reference.

Nutrition support

Nutritional decline is nearly universal in pancreatic cancer and is itself a cause of mortality. Nursing priorities:

• High-calorie, high-protein, low-fat diet
• Small, frequent meals (5–6 per day) — larger meals overwhelm residual enzyme capacity and worsen malabsorption
• PERT with every meal and snack
• Fat-soluble vitamin supplementation (vitamins A, D, E, and K) — malabsorbed in all patients with exocrine insufficiency
• Dietitian referral early in disease course
• Monitor weight, albumin, and prealbumin as markers of nutritional status
• Consider enteral nutrition (jejunal tube feeds) in patients unable to maintain adequate oral intake

End-of-life considerations

Most patients with pancreatic cancer will die of their disease within 2 years of diagnosis. Early palliative care integration — initiated at diagnosis, not just at end of life — improves symptom burden, reduces aggressive end-of-life interventions, and may modestly improve survival in some cancer populations.

Key symptom management domains in advanced PDAC:

• Pain: Opioid titration, celiac plexus block, adjuvant analgesics (gabapentinoids for neuropathic pain)
• Cachexia: Appetite stimulants (megestrol, dronabinol); recognize that cachexia is not simply anorexia — muscle wasting is driven by tumor-secreted factors and cannot be fully reversed by nutritional support alone
• Ascites: Salt restriction, diuretics; large-volume paracentesis for refractory ascites (see liver failure nursing principles)
• Psychological distress: Anxiety and depression are highly prevalent; screening with PHQ-9 and GAD-7; social work and chaplaincy referral
• Goals of care conversations: Nurses are often the first to identify when a patient’s understanding of their prognosis does not match the treatment plan — surfacing these conversations early preserves patient autonomy

NCLEX tips

1. CA 19-9 is NOT a screening test. It is a tumor marker used for monitoring and prognosis — not to diagnose or exclude pancreatic cancer. A normal CA 19-9 does not rule out PDAC.
2. Lewis antigen-negative patients have undetectable CA 19-9 regardless of tumor burden — approximately 5–10% of the population. Do not rely on CA 19-9 to exclude cancer in this group.
3. Courvoisier’s sign = palpable, nontender gallbladder in a jaundiced patient = malignant biliary obstruction until proven otherwise. Gallstones cause gallbladder fibrosis and prevent distension.
4. Body and tail tumors present late — no biliary obstruction, no early jaundice. They are typically unresectable at diagnosis and carry a worse prognosis than head tumors.
5. Whipple procedure removes: head of pancreas + duodenum + distal common bile duct + gallbladder ± distal stomach. Three reconstructions: pancreaticojejunostomy, hepaticojejunostomy, gastrojejunostomy.
6. Delayed gastric emptying (DGE) is the most common Whipple complication (30–40%). It is NOT an anastomotic leak. Management: maintain NGT, keep NPO, prokinetics, advance diet slowly. DGE resolves over days to weeks.
7. Monitor drain amylase on POD 1 and 3 to detect pancreatic fistula. Drain amylase >3× ULN on POD 3 = biochemical leak.
8. Sentinel bleed = a small amount of fresh blood from a drain or NGT after Whipple, occurring days 5–14. It is a warning sign of impending major post-pancreatectomy hemorrhage from pseudoaneurysm formation. Report immediately — do not dismiss as minor.
9. Steatorrhea = foul, oily, floating stools = exocrine insufficiency = give PERT with every meal and snack. Without PERT, fat-soluble vitamins (A, D, E, K) are malabsorbed.
10. New-onset diabetes in an older adult without obesity or family history should raise suspicion for occult pancreatic cancer — it can be a paraneoplastic presentation, not just a risk factor.
11. Trousseau’s sign (migratory thrombophlebitis) is a paraneoplastic phenomenon of visceral cancers, especially pancreatic cancer. Distinguish from Trousseau’s sign of hypocalcemia (carpopedal spasm with BP cuff).
12. FOLFIRINOX: oxaliplatin cold sensitivity — patients must avoid cold foods, beverages, and surfaces. Throat tightening (laryngopharyngeal dysesthesia) is neuropathic, not allergic. Still report it.
13. Post-total pancreatectomy diabetes is brittle — glucagon is also lost, not just insulin. Hypoglycemia risk is greater than classic type 1 DM. Liberal glucose thresholds; educate family about emergency hypoglycemia management.
14. ERCP biliary stent: monitor for cholangitis — Charcot’s triad = fever + jaundice + RUQ pain. Reynolds’ pentad adds hypotension + altered mental status = septic cholangitis, a surgical emergency.
15. VTE risk in pancreatic cancer is among the highest of all solid tumors (Trousseau’s syndrome). Post-Whipple + malignancy + immobility = triple risk. SCDs + LMWH when drain output allows.
16. Semi-Fowler’s position post-Whipple reduces anastomotic tension and aspiration risk.
17. Gemcitabine can cause capillary leak syndrome — monitor for peripheral edema, pleural effusion, and sudden respiratory deterioration. Report new weight gain or dyspnea during gemcitabine therapy.
18. CA 19-9 can be elevated in cholangitis and biliary obstruction even without cancer — do not interpret in an icteric patient until after biliary decompression.

Internal links

Pancreatic cancer intersects with multiple nursing specialties covered elsewhere on this site:

• Pancreatitis nursing — chronic pancreatitis as a cancer risk factor; exocrine/endocrine anatomy; enzyme physiology
• Oncology nursing reference — foundational oncology principles: neutropenia management, antiemetic protocols, tumor lysis syndrome, oncologic emergencies
• GI bleed nursing — upper GI bleeding from gastric varices (splenic vein thrombosis in body/tail PDAC); post-procedural hemorrhage management
• Colorectal cancer nursing — GI oncology cluster; chemotherapy toxicity comparison; palliative care principles
• Liver failure nursing — obstructive jaundice management; hepatic complications of biliary obstruction; ascites; coagulopathy
• Diabetes mellitus nursing — post-pancreatectomy diabetes; insulin management; hypoglycemia recognition and treatment
• DVT nursing — Trousseau’s syndrome; VTE prophylaxis; post-operative anticoagulation principles
• Cirrhosis nursing — portal hypertension; hepatic encephalopathy; ascites management in advanced cancer with liver involvement